Elevance Health, Inc. ELV
Composite 56/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 39/100 — a slight mark against it.
Balance-sheet strength ranks 72/100 — a moderate point in its favour. Momentum ranks 65/100 — a moderate point in its favour. Valuation ranks 61/100 — a slight point in its favour.
Growth ranks 39/100 — a slight mark against it. Quality ranks 44/100 — a slight mark against it.
What the company does Elevance Health operates as a diversified U.S. health benefits company across four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It provides health plans, pharmacy services, administrative managed care, and specialty insurance products to Medicare, Medicaid, employer, and individual markets.
Key financials ELV reports ROE 11.1%, ROA 3.8%, and ROCE 8.5%. Margins stand at gross 26.0%, operating 4.6%, and net 2.5%. Revenue grew 1.4% while EPS declined 13.1%. Leverage metrics include debt/equity 0.69, net debt/EBITDA -0.78, and interest coverage 6.19.
Stock health The stock shows strong momentum: +6.44% (3m), +16.71% (6m), +45.29% (12m). RSI(14) is 51.50, indicating neutral momentum. Sideravia scores highlight weak quality (44.1) but attractive valuation (77.2) and positive momentum (68.9).
Price vs fair value ELV trades at a discount of 14.80% versus the analyst mean target of 449.10. - Analysts cite potential margin recovery as a catalyst (Insider Monkey, 2026-08-04). - Rising medical costs remain a concern despite long-term positioning (Insider Monkey, 2026-08-03). - Recent cancer care initiatives are being evaluated for valuation attractiveness (Simply Wall St., 2026-08-01).
Looking forward Forward P/E of 14.35 and PEG of 0.90 suggest undemanding valuation if earnings stabilize. The company’s diversified segments and cost controls may support margin normalization, but execution risks remain tied to medical cost trends.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.